Restylane Skinboosters Vital Lidocaine 1x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Restylane Skinboosters Vital with lidocaine is Galderma's hydration biostimulator: NASHA® stabilised hyaluronic acid at 20 mg/ml delivered as dermal microdeposits, not as a volumetric filler. Its purpose is skin quality — smoothness, elasticity and skin appearance — and it works with its own protocol of three sessions plus maintenance.
- Stabilised HA 20 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Contents 1 syringe × 1.0 ml
- Needle 29G TW
- Protocol 3 sessions / 4 weeks
Composition and technology
- Stabilised hyaluronic acid: 20 mg/ml, of non-animal origin.
- Lidocaine hydrochloride: 3 mg/ml (0.3 %).
- NASHA® technology: the Skinbooster uses the NASHA gel with the smallest particle size in the family. Stabilised — unlike a free hyaluronic acid used in mesotherapy — which prolongs its residence in the dermis and allows the sessions to be spaced further apart.
- Difference from the fillers in the range: Vital is not formulated to project or to correct folds. It is deposited in a distributed manner in the dermis to improve hydration and elasticity, not to create volume.
- Smart Click system: glass syringe with click dosing, allowing deposits of reproducible volume in the multi-puncture technique.
Position within the range: NASHA and OBT
The entire Restylane range is built on two distinct gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that preserve the long hyaluronic acid chains with minimal cross-linking. High resistance and very low tolerance to deformation: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, known as XpresHAn Technology™ in the US market): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high tolerance to deformation: the gel follows the movement of the tissue, so it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, midface, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, without volumetric purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values are taken from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
Improvement of the smoothness, appearance and elasticity of the skin.
- Lower facial third and jawline
- Dorsum of the hands
These are the areas documented in the manufacturer's instructions for use. Use on the neck, décolletage or other areas falls outside the indication and is the responsibility of the practitioner who indicates it.
Technique and treatment protocol
- Injection plane: dermis, preferably its deep portion.
- Needle included: 29G thin wall (TW), disposable. As an alternative, a 30G blunt cannula may be used, creating an entry point beforehand.
- Technique: microdeposits (multi-puncture), with slow injection and minimal pressure.
- Initial protocol: 3 sessions separated by 4 weeks.
- Maintenance: one session every 6 months.
- Manufacturer's dose limits: maximum 5 ml per session and 20 ml per patient per year.
Distinction from Vital Light: Vital is concentrated at 20 mg/ml and is deposited in the deep dermis; Vital Light is concentrated at 12 mg/ml and is deposited in the mid dermis, for thinner skin and more subtle results.
Technical data
| Manufacturer | Q-Med AB (Galderma) — Uppsala, Sweden |
|---|---|
| Active substance | Stabilised hyaluronic acid 20 mg/ml, of non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml (0.3 %) |
| Technology | NASHA® — small particle |
| Presentation | 1 glass syringe of 1.0 ml with Smart Click system |
| Needle | 29G TW (alternative: 30G blunt cannula) |
| Application plane | Dermis, preferably deep |
| Protocol | 3 sessions every 4 weeks; maintenance every 6 months |
| Maximum dose | 5 ml per session · 20 ml per patient per year |
| Sterilisation | Moist heat (syringe contents) / ethylene oxide (needles) |
| Classification | Medical device with CE marking (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight.
- Do not use after the expiry date shown on the packaging.
- Single-use product. Do not reuse or resterilise.
- The pack contains: 1 glass syringe of 1.0 ml with Smart Click system, disposable 29G TW needle, instructions for use and traceability label for the patient record.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; coagulation disorders; history of keloid scarring; active skin inflammation or infection in the area to be treated.
Caution and individual assessment: anticoagulant or antiplatelet therapy (greater risk of haematoma and bleeding at the puncture site); autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection may cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbances, blindness or stroke. Aspiration before injecting and low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before application.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (instructions for use Restylane® Skinboosters™ Vital Lidocaine, Q-Med AB / Galderma). This data sheet does not replace the instructions for use accompanying the product.